Dexcom Stock

Dexcom EBIT

The EBIT of Dexcom (DXCM) as of Jul 21, 2026 is 653.50 M USD. In the previous year, EBIT was 614.30 M USD — a change of 6.38% (higher).

EBIT

653.50 MUSD

YoY

6.38%

Last updated:

In 2026, Dexcom's EBIT was 653.50 M USD, a 6.38% increase from the 614.30 M USD EBIT recorded in the previous year.

The Dexcom EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2024
0.65 base
Jan 1, 2025 (e)
0.96 base
Jan 1, 2026 (e)
1.21 base
Jan 1, 2027 (e)
1.48 base
Jan 1, 2028 (e)
1.83 base
Jan 1, 2029 (e)
2.16 base
Jan 1, 2030 (e)
2.46 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (B USD)
2031 est -
2030 est 2.46
2029 est 2.16
2028 est 1.83
2027 est 1.48
2026 est 1.21
2025 est 0.96
2024 0.65
2023 0.61
2022 0.41
2021 0.29
2020 0.32
2019 0.16
2018 -0.19
2017 -0.04
2016 -0.06
2015 -0.06
2014 -0.02
2013 -0.03
2012 -0.06
2011 -0.04
2010 -0.05
2009 -0.05
2008 -0.05
2007 -0.05
2006 -0.05
2005 -0.03
Access this data via the Eulerpool API

Dexcom Revenue

Dexcom Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
4.03 B USD
653.50 M USD
576.20 M USD
Jan 1, 2025 (e)
4.74 B USD
955.71 M USD
820.47 M USD
Jan 1, 2026 (e)
5.34 B USD
1.21 B USD
984.74 M USD
Jan 1, 2027 (e)
6.00 B USD
1.48 B USD
1.19 B USD
Jan 1, 2028 (e)
6.71 B USD
1.83 B USD
1.48 B USD
Jan 1, 2029 (e)
7.64 B USD
2.16 B USD
1.73 B USD
Jan 1, 2030 (e)
8.43 B USD
2.46 B USD
1.97 B USD
Jan 1, 2031 (e)
8.50 B USD
0.00 USD
0.00 USD

Dexcom Margins

Dexcom stock margins

The Dexcom margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dexcom. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dexcom.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
61.78 %
16.20 %
14.29 %
Jan 1, 2025 (e)
61.78 %
20.17 %
17.32 %
Jan 1, 2026 (e)
61.78 %
22.60 %
18.45 %
Jan 1, 2027 (e)
61.78 %
24.61 %
19.81 %
Jan 1, 2028 (e)
61.78 %
27.33 %
22.03 %
Jan 1, 2029 (e)
61.78 %
28.30 %
22.65 %
Jan 1, 2030 (e)
61.78 %
29.20 %
23.33 %
Jan 1, 2031 (e)
61.78 %
0.00 %
0.00 %

Dexcom Stock analysis

What does Dexcom do? Dexcom Inc is a US medical technology company specializing in the development and manufacturing of medical devices for monitoring blood sugar levels in diabetes. The company was founded in 1999 by Scott Glenn and John Burd and is headquartered in San Diego, California. Dexcom's history began with the development of a continuous glucose sensor by Scott Glenn, who himself has Type 1 diabetes. In 2006, the company received approval from the US Food and Drug Administration (FDA) for its first continuous glucose sensor, which was marketed as the "Dexcom STS". Since then, the company has developed and launched numerous other products. Dexcom's business model is based on offering solutions to improve the quality of life for people with diabetes through the use of modern technology. The company primarily offers continuous glucose monitoring (CGM) systems, which continuously and in real-time monitor blood sugar levels to optimize insulin therapy and avoid hypoglycemia. Dexcom's goal is to make the daily management of diabetes easier and safer, and to improve the quality of life for those affected. Currently, Dexcom offers two CGM systems: the "Dexcom G6" and the "Dexcom G7". The G6 system has been on the market since 2018 and has been used by over one million people worldwide. It consists of three components: a sensor, a transmitter, and a receiver. The sensor is placed under the skin and continuously measures glucose levels in the tissue. The transmitter sends the measurements to the receiver, which displays the current blood sugar level to the patient. Another option is to connect the system to a smartphone app. The G7 system is still in development and is expected to be launched in 2021. It promises even easier handling and longer battery life. Dexcom has also formed partnerships with other companies, such as insulin pump manufacturers like Tandem Diabetes Care, to enable integration of CGM systems into these devices and enable automated insulin therapy. Currently, Dexcom employs over 3,800 people worldwide and operates in over 50 countries. The company has experienced strong growth in recent years and has steadily increased its revenues. In 2019, Dexcom's revenue was approximately $1.5 billion, representing a 43% increase from the previous year. Overall, Dexcom has established itself as a leading provider in the field of continuous glucose monitoring with its innovative products and focus on improving the quality of life for people with diabetes. The company has successfully made the daily lives of millions of individuals worldwide easier and has become an important partner in diabetes care. Dexcom is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Dexcom's EBIT

Dexcom's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Dexcom's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Dexcom's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Dexcom’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Dexcom stock

EBIT of Dexcom is 653.50 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Dexcom

All Key Metrics — Dexcom